首页 > 最新文献

Journal of Clinical Tuberculosis and Other Mycobacterial Diseases最新文献

英文 中文
Adjuvant surgical treatment of non-tuberculous mycobacterial lung disease in chronic thromboembolic pulmonary hypertension: A first case report 慢性血栓栓塞性肺动脉高压非结核分枝杆菌肺病的辅助手术治疗:首例病例报告
IF 1.9 Q3 INFECTIOUS DISEASES Pub Date : 2024-07-02 DOI: 10.1016/j.jctube.2024.100462
F.R. Bertuccio , N. Baio , S. Montini , V. Ferroni , V. Chino , L. Pisanu , M. Russo , I. Giana , A. Cascina , V. Conio , C. Primiceri , G.M. Stella , A.G. Corsico

Pulmonary hypertension (PH) is not considered a known risk factor for non-tuberculous mycobacterial lung disease (NTM-LD), despite that many studies state that incidence is almost equal to other chronic lung diseases. Current standard of care for NTM-LD consists in multidrug antibiotic regimen for several months. However, it results in negative culture conversion in a minority of cases. Therefore, when feasible an adjuvant surgical approach is indicated. In this case report we highlight the importance of multidisciplinary team discussion in providing the best therapeutic strategy in presence of significant comorbidities like chronic thromboembolic pulmonary hypertension.

肺动脉高压(PH)并不被认为是非结核分枝杆菌肺病(NTM-LD)的已知危险因素,尽管许多研究表明其发病率几乎与其他慢性肺病相当。目前治疗非结核分枝杆菌肺病的标准是使用多药抗生素治疗数月。然而,只有少数病例的培养结果为阴性。因此,在可行的情况下,应采用手术辅助治疗。在本病例报告中,我们强调了多学科团队讨论在慢性血栓栓塞性肺动脉高压等重大合并症情况下提供最佳治疗策略的重要性。
{"title":"Adjuvant surgical treatment of non-tuberculous mycobacterial lung disease in chronic thromboembolic pulmonary hypertension: A first case report","authors":"F.R. Bertuccio ,&nbsp;N. Baio ,&nbsp;S. Montini ,&nbsp;V. Ferroni ,&nbsp;V. Chino ,&nbsp;L. Pisanu ,&nbsp;M. Russo ,&nbsp;I. Giana ,&nbsp;A. Cascina ,&nbsp;V. Conio ,&nbsp;C. Primiceri ,&nbsp;G.M. Stella ,&nbsp;A.G. Corsico","doi":"10.1016/j.jctube.2024.100462","DOIUrl":"https://doi.org/10.1016/j.jctube.2024.100462","url":null,"abstract":"<div><p>Pulmonary hypertension (PH) is not considered a known risk factor for non-tuberculous mycobacterial lung disease (NTM-LD), despite that many studies state that incidence is almost equal to other chronic lung diseases. Current standard of care for NTM-LD consists in multidrug antibiotic regimen for several months. However, it results in negative culture conversion in a minority of cases. Therefore, when feasible an adjuvant surgical approach is indicated. In this case report we highlight the importance of multidisciplinary team discussion in providing the best therapeutic strategy in presence of significant comorbidities like chronic thromboembolic pulmonary hypertension.</p></div>","PeriodicalId":37942,"journal":{"name":"Journal of Clinical Tuberculosis and Other Mycobacterial Diseases","volume":"36 ","pages":"Article 100462"},"PeriodicalIF":1.9,"publicationDate":"2024-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2405579424000494/pdfft?md5=7dcc388511cdb04ad46a5cb91c20af6b&pid=1-s2.0-S2405579424000494-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141541007","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Tuberculosis screening for patients on biologic Medications: A Single-Center experience and Society guideline Review, Monroe County, New York, 2018–2021 服用生物制剂药物患者的结核病筛查:2018-2021年纽约州门罗县的单中心经验和学会指南回顾
IF 1.9 Q3 INFECTIOUS DISEASES Pub Date : 2024-06-22 DOI: 10.1016/j.jctube.2024.100460
Tetsuro Maeda , Margaret Connolly , Kelly Thevenet-Morrison , Paul Levy , Mark Utell , Sonal Munsiff , Daniel Croft

Rationale

Biologic medications for immune-mediated inflammatory diseases may increase the risk of tuberculosis (TB) reactivation, but data on screening for TB in low TB prevalence areas are limited.

Objective

To assess the real-world practice patterns of TB screening among prescribers of biologic medications.

Methods

We conducted a retrospective observational study at a single, university-based healthcare facility in a low TB prevalence area. We enrolled adult patients prescribed a biologic medication between October 2018 and December 2021, and collected data on demographics, biologic medications and TB test results. For patients with positive TB tests, further data including prescriber specialty and response to positive tests were obtained. We reviewed pertinent major society guidelines/ consensus statements regarding TB screening among patients treated with biologic medications.

Results

4,085 patients were included. 3024 (74.0%) had at least one screening TB test and 42 were positive. Among patients treated with tumor necrosis factor-alpha (TNFα) inhibitors, 1779 of 2129 patients (83.6%) underwent TB testing and 25 (1.4%) were positive. Most with positive TB test results were prescribed biologic medication by gastroenterology (11 patients, 26%), dermatology (12, 29%), or rheumatology (15, 36%) providers. 32 (76%) patients had imaging and roughly half were treated for latent TB infection. Biologic medications were temporarily held for 27 patients (67%). Nine out of 13 society guidelines recommend TB screening for TNFα inhibitors but have differing recommendations for other biologic medications.

Conclusions

Significant practice pattern differences in TB screening for patients receiving biologic medications exist. Multiple society guidelines continue to recommend TB screening even for drugs with no known increased risk of TB reactivation.

理由治疗免疫介导的炎症性疾病的生物制剂药物可能会增加结核病(TB)再活化的风险,但在结核病低流行地区进行结核病筛查的数据却很有限。方法我们在结核病低流行地区的一所大学医疗机构开展了一项回顾性观察研究。我们招募了 2018 年 10 月至 2021 年 12 月期间开具生物药处方的成年患者,并收集了有关人口统计学、生物药和结核病检测结果的数据。对于结核病检测呈阳性的患者,我们还进一步获得了包括处方者专业和对阳性检测的反应等数据。我们查阅了有关在接受生物药物治疗的患者中进行结核病筛查的主要学会指南/共识声明。3024人(74.0%)至少进行了一次结核病筛查,其中42人呈阳性。在接受肿瘤坏死因子-α(TNFα)抑制剂治疗的患者中,2129 名患者中有 1779 名(83.6%)接受了结核病检测,25 名(1.4%)呈阳性。大多数结核病检测结果呈阳性的患者都接受了消化科(11 人,26%)、皮肤科(12 人,29%)或风湿免疫科(15 人,36%)医生开具的生物制剂药物治疗。32(76%)名患者接受了影像学检查,约半数接受了潜伏肺结核感染治疗。有 27 名患者(67%)暂时停用了生物制剂药物。在 13 份学会指南中,有 9 份建议对 TNFα 抑制剂进行结核病筛查,但对其他生物制剂药物的建议有所不同。多个学会的指南继续建议对结核病进行筛查,即使是已知结核病再激活风险不会增加的药物。
{"title":"Tuberculosis screening for patients on biologic Medications: A Single-Center experience and Society guideline Review, Monroe County, New York, 2018–2021","authors":"Tetsuro Maeda ,&nbsp;Margaret Connolly ,&nbsp;Kelly Thevenet-Morrison ,&nbsp;Paul Levy ,&nbsp;Mark Utell ,&nbsp;Sonal Munsiff ,&nbsp;Daniel Croft","doi":"10.1016/j.jctube.2024.100460","DOIUrl":"https://doi.org/10.1016/j.jctube.2024.100460","url":null,"abstract":"<div><h3>Rationale</h3><p>Biologic medications for immune-mediated inflammatory diseases may increase the risk of tuberculosis (TB) reactivation, but data on screening for TB in low TB prevalence areas are limited.</p></div><div><h3>Objective</h3><p>To assess the real-world practice patterns of TB screening among prescribers of biologic medications.</p></div><div><h3>Methods</h3><p>We conducted a retrospective observational study at a single, university-based healthcare facility in a low TB prevalence area. We enrolled adult patients prescribed a biologic medication between October 2018 and December 2021, and collected data on demographics, biologic medications and TB test results. For patients with positive TB tests, further data including prescriber specialty and response to positive tests were obtained. We reviewed pertinent major society guidelines/ consensus statements regarding TB screening among patients treated with biologic medications.</p></div><div><h3>Results</h3><p>4,085 patients were included. 3024 (74.0%) had at least one screening TB test and 42 were positive. Among patients treated with tumor necrosis factor-alpha (TNFα) inhibitors, 1779 of 2129 patients (83.6%) underwent TB testing and 25 (1.4%) were positive. Most with positive TB test results were prescribed biologic medication by gastroenterology (11 patients, 26%), dermatology (12, 29%), or rheumatology (15, 36%) providers. 32 (76%) patients had imaging and roughly half were treated for latent TB infection. Biologic medications were temporarily held for 27 patients (67%). Nine out of 13 society guidelines recommend TB screening for TNFα inhibitors but have differing recommendations for other biologic medications.</p></div><div><h3>Conclusions</h3><p>Significant practice pattern differences in TB screening for patients receiving biologic medications exist. Multiple society guidelines continue to recommend TB screening even for drugs with no known increased risk of TB reactivation.</p></div>","PeriodicalId":37942,"journal":{"name":"Journal of Clinical Tuberculosis and Other Mycobacterial Diseases","volume":"36 ","pages":"Article 100460"},"PeriodicalIF":1.9,"publicationDate":"2024-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2405579424000470/pdfft?md5=aaa541c0d07cf00d1f7dc63ad5ee8082&pid=1-s2.0-S2405579424000470-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141483898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Systematic review: Global host range, case fatality and detection rates of Mycobacterium ulcerans in humans and potential environmental sources 系统回顾:人类溃疡分枝杆菌的全球宿主范围、病死率和检出率以及潜在的环境来源
IF 1.9 Q3 INFECTIOUS DISEASES Pub Date : 2024-06-21 DOI: 10.1016/j.jctube.2024.100457
Serges Tchatchouang , Chris Andre Mbongue Mikangue , Sebastien Kenmoe , Arnol Bowo-Ngandji , Gadji Mahamat , Jean Thierry Ebogo-Belobo , Donatien Serge Mbaga , Joseph Rodrigue Foe-Essomba , Hycenth Numfor , Ginette Irma Kame-Ngasse , Inès Nyebe , Jean Bosco Taya-Fokou , Cromwel Zemnou-Tepap , Jacqueline Félicité Yéngué , Jeannette Nina Magoudjou-Pekam , Larissa Gertrude Djukouo , Marie Antoinette Kenmegne Noumbissi , Raoul Kenfack-Momo , Sabine Aimee Touangnou-Chamda , Alfloditte Flore Feudjio , Sara Eyangoh

Fundamental aspects of the epidemiology and ecology of Mycobacterium ulcerans (MU) infections including disease burden, host range, reservoir, intermediate hosts, vector and mode of transmission are poorly understood. Understanding the global distribution and burden of MU infections is a paramount to fight against Buruli ulcer (BU). Four databases were queried from inception through December 2023. After critical review of published resources on BU, 155 articles (645 records) published between 1987 and 2023 from 16 countries were selected for this review. Investigating BU in from old endemic and new emerging foci has allowed detection of MU in humans, animals, plants and various environmental samples with prevalence from 0 % up to 100 % depending of the study design. A case fatality rate between 0.0 % and 50 % was described from BU patients and deaths occurred in Central African Republic, Gabon, Democratic Republic of the Congo, Burkina Faso and Australia. The prevalence of MU in humans was higher in Africa. Nucleic Acid Amplification Tests (NAAT) and non-NAAT were performed in > 38 animal species. MU has been recovered in culture from possum faeces, aquatic bugs and koala. More than 7 plant species and several environmental samples have been tested positive for MU. This review provided a comprehensive set of data on the updates of geographic distribution, the burden of MU infections in humans, and the host range of MU in non-human organisms. Although MU have been found in a wide range of environmental samples, only few of these have revealed the viability of the mycobacterium and the replicative non-human reservoirs of MU remain to be explored. These findings should serve as a foundation for further research on the reservoirs, intermediate hosts and transmission routes of MU.

人们对溃疡分枝杆菌(MU)感染的流行病学和生态学的基本方面,包括疾病负担、宿主范围、储库、中间宿主、传播媒介和传播方式知之甚少。了解溃疡分枝杆菌感染的全球分布和负担对防治布路里溃疡(BU)至关重要。我们查询了从开始到 2023 年 12 月的四个数据库。在对已发表的布路里溃疡相关资料进行严格审查后,本综述选择了 1987 年至 2023 年期间发表的来自 16 个国家的 155 篇文章(645 条记录)。通过对旧流行病区和新出现病区的 BU 进行调查,可以在人类、动物、植物和各种环境样本中检测到 MU,其流行率从 0% 到 100% 不等,具体取决于研究设计。在中非共和国、加蓬、刚果民主共和国、布基纳法索和澳大利亚,BU 患者的病死率在 0.0 % 到 50 % 之间。MU在非洲人体内的流行率较高。在 38 种动物中进行了核酸扩增试验(NAAT)和非 NAAT 试验。在负鼠粪便、水生昆虫和考拉的培养物中发现了 MU。超过 7 种植物和一些环境样本的 MU 检测结果呈阳性。这篇综述提供了一套全面的数据,包括地理分布的最新情况、人类感染 MU 的负担以及 MU 在非人类生物中的宿主范围。虽然在广泛的环境样本中发现了 MU,但其中只有少数样本揭示了分枝杆菌的生存能力,而 MU 的非人类复制库仍有待探索。这些发现应作为进一步研究 MU 的储库、中间宿主和传播途径的基础。
{"title":"Systematic review: Global host range, case fatality and detection rates of Mycobacterium ulcerans in humans and potential environmental sources","authors":"Serges Tchatchouang ,&nbsp;Chris Andre Mbongue Mikangue ,&nbsp;Sebastien Kenmoe ,&nbsp;Arnol Bowo-Ngandji ,&nbsp;Gadji Mahamat ,&nbsp;Jean Thierry Ebogo-Belobo ,&nbsp;Donatien Serge Mbaga ,&nbsp;Joseph Rodrigue Foe-Essomba ,&nbsp;Hycenth Numfor ,&nbsp;Ginette Irma Kame-Ngasse ,&nbsp;Inès Nyebe ,&nbsp;Jean Bosco Taya-Fokou ,&nbsp;Cromwel Zemnou-Tepap ,&nbsp;Jacqueline Félicité Yéngué ,&nbsp;Jeannette Nina Magoudjou-Pekam ,&nbsp;Larissa Gertrude Djukouo ,&nbsp;Marie Antoinette Kenmegne Noumbissi ,&nbsp;Raoul Kenfack-Momo ,&nbsp;Sabine Aimee Touangnou-Chamda ,&nbsp;Alfloditte Flore Feudjio ,&nbsp;Sara Eyangoh","doi":"10.1016/j.jctube.2024.100457","DOIUrl":"https://doi.org/10.1016/j.jctube.2024.100457","url":null,"abstract":"<div><p>Fundamental aspects of the epidemiology and ecology of <em>Mycobacterium ulcerans</em> (MU) infections including disease burden, host range, reservoir, intermediate hosts, vector and mode of transmission are poorly understood.<!--> <!-->Understanding the global distribution and burden of MU infections is a paramount to fight against Buruli ulcer (BU). Four databases were queried<!--> <!-->from inception through December 2023. After critical review of published resources on BU, 155 articles (645 records) published between 1987 and 2023 from 16 countries were selected for this review. Investigating BU in from old endemic and new emerging foci has allowed detection of MU in humans, animals, plants and various environmental samples with prevalence from 0 % up to 100 % depending of the study design. A case fatality rate between 0.0 % and 50 % was described from BU patients and deaths occurred in Central African Republic, Gabon, Democratic Republic of the Congo, Burkina Faso and Australia. The prevalence of MU in humans was higher in Africa. Nucleic Acid Amplification Tests (NAAT) and non-NAAT were performed in &gt; 38 animal species. MU has been recovered in culture from possum faeces, aquatic bugs and koala. More than 7 plant species and several environmental samples have been tested positive for MU. This review provided a comprehensive set of data on the updates of geographic distribution, the burden of MU infections in humans, and the host range of MU in non-human organisms. Although MU have been found in a wide range of environmental samples, only few of these have revealed the viability of the <em>mycobacterium</em> and the replicative non-human reservoirs of MU remain to be explored. These findings should serve as a foundation for further research on the reservoirs, intermediate hosts and transmission routes of MU.</p></div>","PeriodicalId":37942,"journal":{"name":"Journal of Clinical Tuberculosis and Other Mycobacterial Diseases","volume":"36 ","pages":"Article 100457"},"PeriodicalIF":1.9,"publicationDate":"2024-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2405579424000445/pdfft?md5=798db4e4d80baaa6c7f4dc6f71b26dc9&pid=1-s2.0-S2405579424000445-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141444457","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Diagnostic performance of matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS) in bronchoalveolar lavage fluid for pulmonary tuberculosis in HIV-infected patients 基质辅助激光解吸附电离飞行时间质谱(MALDI-TOF MS)对艾滋病毒感染者支气管肺泡灌洗液中肺结核的诊断性能
IF 2 Q3 INFECTIOUS DISEASES Pub Date : 2024-06-17 DOI: 10.1016/j.jctube.2024.100459
Mei Zhang , Hongwei Zhang , Benyong Yan , Meixin Ren , Wen Wang , Tong Zhang

Introduction

Pulmonary tuberculosis (PTB) remains a significant health concern, particularly in individuals infected with human immunodeficiency virus (HIV) who are more susceptible to developing active TB disease. Early and accurate diagnosis of TB is crucial for effective treatment and prevention of transmission. This study aims to evaluate the potential of matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOFMS) analysis of bronchoalveolar lavage fluid (BALF) for diagnosis of suspected PTB in HIV-infected patients.

Methods

This retrospective study recruited 60 HIV-infected patients with suspected PTB presenting with respiratory symptoms and abnormal chest radiographs between January 2022 and June 2023. BALF samples were collected and subjected to analysis using MALDI-TOF MS, GeneXpert, acid-fast bacilli (AFB) smear and culture. And their diagnostic performance was compared.

Results

The sensitivity of MALDI⁃TOFMS for diagnosing PTB was 83.3 %, which was better than that of smear 11.9 %, culture 40.5 % or Xpert38.1 % (all p < 0.01). The area under the curve (AUC) value of MALDI⁃TOFMS was 0.889, which was better than that of smear 0.532, culture 0.675 or Xpert 0.690 (all p < 0.01). The katG315 and rpoB-RRDR 511 mutations were detected by the MALDI⁃TOFMS in two patients.

Conclusion

Nucleotide MALDI-TOFMS has a good clinical performance for rapid diagnosis of PTB from BALF samples in HIV infected patients, and detects mutations of TB simultaneously.

导言肺结核(PTB)仍然是一个重大的健康问题,尤其是感染了人类免疫缺陷病毒(HIV)的人更容易患活动性肺结核病。结核病的早期准确诊断对于有效治疗和预防传播至关重要。本研究旨在评估基质辅助激光解吸附电离飞行时间质谱(MALDI-TOFMS)分析支气管肺泡灌洗液(BALF)诊断艾滋病病毒感染者疑似 PTB 的潜力。研究人员收集了肺泡样本,并使用 MALDI-TOF MS、GeneXpert、酸性无菌杆菌(AFB)涂片和培养进行分析。结果 MALDI⁃TOFMS诊断PTB的灵敏度为83.3%,优于涂片11.9%、培养40.5%和Xpert38.1%(均为P <0.01)。MALDI⁃TOFMS的曲线下面积(AUC)值为0.889,优于涂片的0.532、培养的0.675或Xpert的0.690(均为0.01)。结论核苷酸MALDI⁃TOFMS对HIV感染者BALF标本快速诊断PTB有较好的临床效果,可同时检测结核病的突变。
{"title":"Diagnostic performance of matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS) in bronchoalveolar lavage fluid for pulmonary tuberculosis in HIV-infected patients","authors":"Mei Zhang ,&nbsp;Hongwei Zhang ,&nbsp;Benyong Yan ,&nbsp;Meixin Ren ,&nbsp;Wen Wang ,&nbsp;Tong Zhang","doi":"10.1016/j.jctube.2024.100459","DOIUrl":"https://doi.org/10.1016/j.jctube.2024.100459","url":null,"abstract":"<div><h3>Introduction</h3><p>Pulmonary tuberculosis (PTB) remains a significant health concern, particularly in individuals infected with human immunodeficiency virus (HIV) who are more susceptible to developing active TB disease. Early and accurate diagnosis of TB is crucial for effective treatment and prevention of transmission. This study aims to evaluate the potential of matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOFMS) analysis of bronchoalveolar lavage fluid (BALF) for diagnosis of suspected PTB in HIV-infected patients.</p></div><div><h3>Methods</h3><p>This retrospective study recruited 60 HIV-infected patients with suspected PTB presenting with respiratory symptoms and abnormal chest radiographs between January 2022 and June 2023. BALF samples were collected and subjected to analysis using MALDI-TOF MS, GeneXpert, acid-fast bacilli (AFB) smear and culture. And their diagnostic performance was compared.</p></div><div><h3>Results</h3><p>The sensitivity of MALDI⁃TOFMS for diagnosing PTB was 83.3 %, which was better than that of smear 11.9 %, culture 40.5 % or Xpert38.1 % (all <em>p</em> &lt; 0.01). The area under the curve (AUC) value of MALDI⁃TOFMS was 0.889, which was better than that of smear 0.532, culture 0.675 or Xpert 0.690 (all <em>p</em> &lt; 0.01). The katG315 and rpoB-RRDR 511 mutations were detected by the MALDI⁃TOFMS in two patients.</p></div><div><h3>Conclusion</h3><p>Nucleotide MALDI-TOFMS has a good clinical performance for rapid diagnosis of PTB from BALF samples in HIV infected patients, and detects mutations of TB simultaneously.</p></div>","PeriodicalId":37942,"journal":{"name":"Journal of Clinical Tuberculosis and Other Mycobacterial Diseases","volume":"36 ","pages":"Article 100459"},"PeriodicalIF":2.0,"publicationDate":"2024-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2405579424000469/pdfft?md5=4f39b2acf5cb5f61d2d541743612fd03&pid=1-s2.0-S2405579424000469-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141423394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mycobacterium tuberculosis and host interactions in the manifestation of tuberculosis 结核分枝杆菌和宿主在结核病表现中的相互作用
IF 2 Q3 INFECTIOUS DISEASES Pub Date : 2024-06-14 DOI: 10.1016/j.jctube.2024.100458
Shadi Abbasnia , Amir Mohammad Hashem Asnaashari , Hiva Sharebiani , Saman Soleimanpour , Arman Mosavat , Seyed Abdolrahim Rezaee

The final step of epigenetic processes is changing the gene expression in a new microenvironment in the body, such as neuroendocrine changes, active infections, oncogenes, or chemical agents. The case of tuberculosis (TB) is an outcome of Mycobacterium tuberculosis (M.tb) and host interaction in the manifestation of active and latent TB or clearance. This comprehensive review explains and interprets the epigenetics findings regarding gene expressions on the host-pathogen interactions in the development and progression of tuberculosis. This review introduces novel insights into the complicated host-pathogen interactions, discusses the challengeable results, and shows the gaps in the clear understanding of M.tb behavior. Focusing on the biological phenomena of host-pathogen interactions, the epigenetic changes, and their outcomes provides a promising future for developing effective TB immunotherapies when converting gene expression toward appropriate host immune responses gradually becomes attainable. Overall, this review may shed light on the dark sides of TB pathogenesis as a life-threatening disease. Therefore, it may support effective planning and implementation of epigenetics approaches for introducing proper therapies or effective vaccines.

表观遗传过程的最后一步是在体内新的微环境(如神经内分泌变化、活动性感染、癌基因或化学制剂)中改变基因表达。结核病(TB)是结核分枝杆菌(M.tb)与宿主相互作用的结果,表现为活动性和潜伏性结核病或清除。这篇综合性综述解释并诠释了在结核病的发展和进程中宿主与病原体相互作用的基因表达方面的表观遗传学发现。这篇综述介绍了对复杂的宿主-病原体相互作用的新见解,讨论了具有挑战性的结果,并指出了在清楚了解 M.tb 行为方面存在的差距。关注宿主-病原体相互作用的生物学现象、表观遗传学变化及其结果,为开发有效的结核病免疫疗法提供了一个充满希望的未来,因为将基因表达转化为适当的宿主免疫反应已逐渐成为可能。总之,本综述可以揭示结核病作为一种威胁生命的疾病的发病机制的阴暗面。因此,它可以支持表观遗传学方法的有效规划和实施,以引入适当的疗法或有效的疫苗。
{"title":"Mycobacterium tuberculosis and host interactions in the manifestation of tuberculosis","authors":"Shadi Abbasnia ,&nbsp;Amir Mohammad Hashem Asnaashari ,&nbsp;Hiva Sharebiani ,&nbsp;Saman Soleimanpour ,&nbsp;Arman Mosavat ,&nbsp;Seyed Abdolrahim Rezaee","doi":"10.1016/j.jctube.2024.100458","DOIUrl":"10.1016/j.jctube.2024.100458","url":null,"abstract":"<div><p>The final step of epigenetic processes is changing the gene expression in a new microenvironment in the body, such as neuroendocrine changes, active infections, oncogenes, or chemical agents. The case of tuberculosis (TB) is an outcome of <em>Mycobacterium tuberculosis</em> (<em>M.tb</em>) and host interaction in the manifestation of active and latent TB or clearance. This comprehensive review explains and interprets the epigenetics findings regarding gene expressions on the host-pathogen interactions in the development and progression of tuberculosis. This review introduces novel insights into the complicated host-pathogen interactions, discusses the challengeable results, and shows the gaps in the clear understanding of <em>M.tb</em> behavior. Focusing on the biological phenomena of host-pathogen interactions, the epigenetic changes, and their outcomes provides a promising future for developing effective TB immunotherapies when converting gene expression toward appropriate host immune responses gradually becomes attainable. Overall, this review may shed light on the dark sides of TB pathogenesis as a life-threatening disease. Therefore, it may support effective planning and implementation of epigenetics approaches for introducing proper therapies or effective vaccines.</p></div>","PeriodicalId":37942,"journal":{"name":"Journal of Clinical Tuberculosis and Other Mycobacterial Diseases","volume":"36 ","pages":"Article 100458"},"PeriodicalIF":2.0,"publicationDate":"2024-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2405579424000457/pdfft?md5=49b803c0909a47e7c7ff0c52a0d64725&pid=1-s2.0-S2405579424000457-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141401840","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nontuberculous mycobacterial infection in Wisconsin children and adolescents 威斯康星州儿童和青少年的非结核分枝杆菌感染
IF 2 Q3 INFECTIOUS DISEASES Pub Date : 2024-06-12 DOI: 10.1016/j.jctube.2024.100456
Bryan J. Vonasek , Danièle Gusland , Julie Tans-Kersten , Elizabeth A. Misch , Suzanne N. Gibbons-Burgener

Background

The epidemiology of nontuberculous mycobacteria (NTM) infections in the pediatric population is not well described. We estimated the incidence of NTM infection in Wisconsin children and adolescents, and the frequency and type of infection caused by different NTM pathogens. Associations between NTM infection and race/ethnicity and social disadvantage, respectively, were also investigated.

Methods

This retrospective cohort study evaluated reports of NTM infection in Wisconsin residents under 18 years of age submitted to a state-wide database between 2011 and 2018. Demographics of the cohort, including a social disadvantage score (Area Deprivation Index (ADI)), are described. Specimen type and NTM species are enumerated for reported isolates.

Results

There were 224 NTM isolates from 212 children and adolescents. Median age of participants was 3 years; 55 % were female. Cumulative incidence did not vary significantly between the larger racial groups or for the various ADI score groups. Compared to white participants (157), there was a significantly lower cumulative incidence of NTM infection in multiracial individuals (2). Mycobacterium avium complex (MAC) was the most frequently isolated organism (69 %). The majority of isolates (52 %) were from skin and soft tissue, which included lymph node specimens. Annual incidence did not vary significantly over the study period.

Conclusions

The epidemiology of pediatric NTM infections in this cohort is consistent with previous pediatric reports of higher rate of infection in females and predominance of skin and soft tissue infections. Disparities in disease burden across racial/ethnic and socio-economic groups were not demonstrated, but these factors should be further explored in larger pediatric studies of diverse U.S. populations.

背景儿科非结核分枝杆菌(NTM)感染的流行病学尚未得到很好的描述。我们估算了威斯康星州儿童和青少年非结核分枝杆菌感染的发病率,以及不同非结核分枝杆菌病原体引起感染的频率和类型。这项回顾性队列研究评估了 2011 年至 2018 年间提交给全州数据库的威斯康星州 18 岁以下居民 NTM 感染报告。研究描述了队列的人口统计学特征,包括社会贫困指数(ADI)。结果从 212 名儿童和青少年中分离出 224 株 NTM。参与者的中位年龄为 3 岁;55% 为女性。在较大的种族群体之间或不同的 ADI 评分群体之间,累积发病率没有明显差异。与白人参与者(157 人)相比,多种族人群的非结核分枝杆菌感染累积发病率明显较低(2)。分枝杆菌(MAC)是最常见的分离菌(69%)。大多数分离菌(52%)来自皮肤和软组织,包括淋巴结标本。结论:该队列中的儿科 NTM 感染流行病学与之前的儿科报告一致,即女性感染率较高,且以皮肤和软组织感染为主。不同种族/族裔和社会经济群体之间的疾病负担差异未得到证实,但这些因素应在对美国不同人群进行的更大规模的儿科研究中进一步探讨。
{"title":"Nontuberculous mycobacterial infection in Wisconsin children and adolescents","authors":"Bryan J. Vonasek ,&nbsp;Danièle Gusland ,&nbsp;Julie Tans-Kersten ,&nbsp;Elizabeth A. Misch ,&nbsp;Suzanne N. Gibbons-Burgener","doi":"10.1016/j.jctube.2024.100456","DOIUrl":"https://doi.org/10.1016/j.jctube.2024.100456","url":null,"abstract":"<div><h3>Background</h3><p>The epidemiology of nontuberculous mycobacteria (NTM) infections in the pediatric population is not well described. We estimated the incidence of NTM infection in Wisconsin children and adolescents, and the frequency and type of infection caused by different NTM pathogens. Associations between NTM infection and race/ethnicity and social disadvantage, respectively, were also investigated.</p></div><div><h3>Methods</h3><p>This retrospective cohort study evaluated reports of NTM infection in Wisconsin residents under 18 years of age submitted to a state-wide database between 2011 and 2018. Demographics of the cohort, including a social disadvantage score (Area Deprivation Index (ADI)), are described. Specimen type and NTM species are enumerated for reported isolates.</p></div><div><h3>Results</h3><p>There were 224 NTM isolates from 212 children and adolescents. Median age of participants was 3 years; 55 % were female. Cumulative incidence did not vary significantly between the larger racial groups or for the various ADI score groups. Compared to white participants (157), there was a significantly lower cumulative incidence of NTM infection in multiracial individuals (2). <em>Mycobacterium avium</em> complex (MAC) was the most frequently isolated organism (69 %). The majority of isolates (52 %) were from skin and soft tissue, which included lymph node specimens. Annual incidence did not vary significantly over the study period.</p></div><div><h3>Conclusions</h3><p>The epidemiology of pediatric NTM infections in this cohort is consistent with previous pediatric reports of higher rate of infection in females and predominance of skin and soft tissue infections. Disparities in disease burden across racial/ethnic and socio-economic groups were not demonstrated, but these factors should be further explored in larger pediatric studies of diverse U.S. populations.</p></div>","PeriodicalId":37942,"journal":{"name":"Journal of Clinical Tuberculosis and Other Mycobacterial Diseases","volume":"36 ","pages":"Article 100456"},"PeriodicalIF":2.0,"publicationDate":"2024-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2405579424000433/pdfft?md5=5d3bcb74fd0ab59bf845e3b0134fda80&pid=1-s2.0-S2405579424000433-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141325715","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A review of 280 nasopharyngeal tuberculosis cases and the effectiveness of antituberculosis treatments 280 例鼻咽结核病例和抗结核治疗效果回顾
IF 2 Q3 INFECTIOUS DISEASES Pub Date : 2024-06-09 DOI: 10.1016/j.jctube.2024.100455
Yun Jin Kang , Jin-Hee Cho

Objectives

Nasopharyngeal tuberculosis is a rare form of tuberculosis in which Mycobacterium tuberculosis infects the nasopharyngeal tissue. In this study, we analyzed key clinical features to prevent misdiagnosis and to raise awareness of the condition, while recommending suitable treatments. We also report a case of nasopharyngeal tuberculosis presenting with nasal congestion and intermittent ear fullness, contributing valuable educational insight for diagnosis.

Methods

Demographic and clinical data from patients with nasopharyngeal tuberculosis were collected from PubMed, Embase, Web of Science and the Cochrane Central Register of Controlled Trials up to September 2022. In total, 280 patients from 69 studies were analyzed.

Results

Reports indicate that the incidence of nasopharyngeal tuberculosis has doubled every decade, particularly in Asia. Most patients are female, presenting with granulomatous pathology and findings such as masses, lymphoid hyperplasia, polypoid formations, or swelling on endoscopic examination. Common symptoms include nasal obstruction, hearing impairment, sore throat, and dysphagia, usually accompanied by cervical lymphadenopathy. The mean duration from symptom onset to diagnosis is ∼2.88 months, and the average time from the start of treatment to resolution of symptoms is ∼ 4.90 months. The antituberculosis treatment regimen and duration are significantly associated with the time to resolution (r = −0.648, p = 0.003 and r = 0.584, p = 0.028, respectively).

Conclusion

These results suggest that an extended regimen of antituberculosis drugs may expedite symptom relief. However, there is a need for more standardized data on patient outcomes and treatment efficacy due to the current lack of comprehensive data.

目的鼻咽结核是结核分枝杆菌感染鼻咽组织的一种罕见结核病。在本研究中,我们分析了鼻咽结核的主要临床特征,以防止误诊,提高人们对该病的认识,同时推荐合适的治疗方法。我们还报告了一例表现为鼻塞和间歇性耳部胀满的鼻咽部结核病例,为诊断提供了有价值的教育启示。方法:我们从 PubMed、Embase、Web of Science 和 Cochrane Central Register of Controlled Trials 收集了截至 2022 年 9 月的鼻咽部结核患者的人口统计学和临床数据。结果报告显示,鼻咽结核的发病率每十年翻一番,尤其是在亚洲。大多数患者为女性,表现为肉芽肿性病变,内窥镜检查发现肿块、淋巴增生、息肉样形成或肿胀。常见症状包括鼻塞、听力障碍、咽喉痛和吞咽困难,通常伴有颈淋巴结病。从症状出现到确诊的平均时间为 2.88 个月,从开始治疗到症状缓解的平均时间为 4.90 个月。抗结核治疗方案和疗程与症状缓解时间显著相关(分别为 r = -0.648,p = 0.003 和 r =0.584,p = 0.028)。然而,由于目前缺乏全面的数据,因此需要更多有关患者预后和治疗效果的标准化数据。
{"title":"A review of 280 nasopharyngeal tuberculosis cases and the effectiveness of antituberculosis treatments","authors":"Yun Jin Kang ,&nbsp;Jin-Hee Cho","doi":"10.1016/j.jctube.2024.100455","DOIUrl":"10.1016/j.jctube.2024.100455","url":null,"abstract":"<div><h3>Objectives</h3><p>Nasopharyngeal tuberculosis is a rare form of tuberculosis in which Mycobacterium tuberculosis infects the nasopharyngeal tissue. In this study, we analyzed key clinical features to prevent misdiagnosis and to raise awareness of the condition, while recommending suitable treatments. We also report a case of nasopharyngeal tuberculosis presenting with nasal congestion and intermittent ear fullness, contributing valuable educational insight for diagnosis.</p></div><div><h3>Methods</h3><p>Demographic and clinical data from patients with nasopharyngeal tuberculosis were collected from PubMed, Embase, Web of Science and the Cochrane Central Register of Controlled Trials up to September 2022. In total, 280 patients from 69 studies were analyzed.</p></div><div><h3>Results</h3><p>Reports indicate that the incidence of nasopharyngeal tuberculosis has doubled every decade, particularly in Asia. Most patients are female, presenting with granulomatous pathology and findings such as masses, lymphoid hyperplasia, polypoid formations, or swelling on endoscopic examination. Common symptoms include nasal obstruction, hearing impairment, sore throat, and dysphagia, usually accompanied by cervical lymphadenopathy. The mean duration from symptom onset to diagnosis is ∼2.88 months, and the average time from the start of treatment to resolution of symptoms is ∼ 4.90 months. The antituberculosis treatment regimen and duration are significantly associated with the time to resolution (r = −0.648, p = 0.003 and r = 0.584, p = 0.028, respectively).</p></div><div><h3>Conclusion</h3><p>These results suggest that an extended regimen of antituberculosis drugs may expedite symptom relief. However, there is a need for more standardized data on patient outcomes and treatment efficacy due to the current lack of comprehensive data.</p></div>","PeriodicalId":37942,"journal":{"name":"Journal of Clinical Tuberculosis and Other Mycobacterial Diseases","volume":"36 ","pages":"Article 100455"},"PeriodicalIF":2.0,"publicationDate":"2024-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2405579424000421/pdfft?md5=10cb66fec806702109c3314df16066cd&pid=1-s2.0-S2405579424000421-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141403880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Loss to follow-up among people living with HIV on tuberculosis preventive treatment at four regional referral hospitals, Uganda, 2019–2021 2019-2021年乌干达四个地区转诊医院接受结核病预防治疗的艾滋病毒感染者失去随访的情况
IF 2 Q3 INFECTIOUS DISEASES Pub Date : 2024-06-08 DOI: 10.1016/j.jctube.2024.100454
Edirisa Juniour Nsubuga , Deus Lukoye , Steven N. Kabwama , Stella Martha Migamba , Allan Komakech , Elayete Sarah , Rose Nampeera , Rashida Nakazzi , Saharu Magona Nerima , Jireh Kirabo , Lilian Bulage , Benon Kwesiga , Alex Riolexus Ario

Introduction

Tuberculosis (TB) remains the leading cause of death among people living with HIV (PLHIV). TB preventive treatment (TPT) can prevent active TB infection in PLHIV for several years after it is completed. During 2019–2021, the six-month course of TPT (using isoniazid) was the most readily available in Uganda; however, program data indicated a TPT program loss to follow-up (LTFU) rate of 12 % during this period. We evaluated factors associated with TPT LTFU among PLHIV in four regional referral hospitals (RRHs) in Uganda from 2019 to 2021.

Methods

We abstracted program data from TPT registers on patient LTFU at Masaka, Mbale, Mubende, and Jinja RRHs. Additional data collected included client demographics, duration on HIV antiretroviral therapy (ART), year of TPT initiation, adherence, and point of entry. LTFU was defined as the failure to finish six consecutive months of isoniazid without stopping for more than two months at a time. We conducted bivariate analysis using the chi-square test for independence. Variables with p < 0.05 in bivariate analysis were included in a logistic regression model to establish independent factors associated with LTFU.

Results

Overall, 24,206 clients were started on TPT in the four RRHs. Their median age was 40 years (range, 1–90 years), and 15,962 (66 %) were female. A total of 22,260 (92 %) had TPT adherence >95 %. Independent factors associated with LTFU included being on ART for <3 months (AOR: 3.1, 95 % CI: 2.1–4.5) and 20–24 years (AOR: 4.7, 95 % CI: 1.9–12) or 25–29 years (AOR: 3.3, 95 % CI: 1.3–8.2) compared to 15–19 years.

Conclusions

PLHIV just starting ART and young adults had higher odds of being LTFU from TPT during 2019–2021 in the four RRHs. Close follow-up of PLHIV aged 20–29 years and those newly initiated on ART could improve TPT completion.

导言结核病(TB)仍然是艾滋病病毒感染者(PLHIV)死亡的主要原因。结核病预防性治疗(TPT)可在完成治疗后的数年内预防艾滋病病毒感染者的活动性结核病感染。2019-2021 年期间,乌干达最容易获得的是六个月疗程的 TPT(使用异烟肼);然而,项目数据显示,在此期间,TPT 项目的随访损失率(LTFU)为 12%。我们评估了 2019 年至 2021 年乌干达四个地区转诊医院(RRHs)中 PLHIV 的 TPT LTFU 相关因素。方法我们从马萨卡、姆巴莱、穆本德和金贾 RRHs 的 TPT 登记簿中抽取了有关患者 LTFU 的项目数据。收集的其他数据包括患者的人口统计学特征、接受艾滋病抗逆转录病毒疗法(ART)的持续时间、开始接受 TPT 的年份、依从性和进入点。LTFU的定义是未能完成连续6个月的异烟肼治疗,且每次停药时间超过两个月。我们使用卡方检验进行了双变量分析。双变量分析中 p < 0.05 的变量被纳入逻辑回归模型,以确定与 LTFU 相关的独立因素。他们的年龄中位数为 40 岁(1-90 岁不等),15,962 人(66%)为女性。共有 22,260 人(92%)对 TPT 的依从性达到了 95%。与 LTFU 相关的独立因素包括接受 ART 3 个月(AOR:3.1,95 % CI:2.1-4.5)和 20-24 岁(AOR:4.7,95 % CI:1.9-12)或 25-29 岁(AOR:3.3,95 % CI:1.3-8.2)与 15-19 岁相比。对20-29岁的艾滋病病毒感染者和新开始接受抗逆转录病毒疗法的艾滋病病毒感染者进行密切随访可提高TPT的完成率。
{"title":"Loss to follow-up among people living with HIV on tuberculosis preventive treatment at four regional referral hospitals, Uganda, 2019–2021","authors":"Edirisa Juniour Nsubuga ,&nbsp;Deus Lukoye ,&nbsp;Steven N. Kabwama ,&nbsp;Stella Martha Migamba ,&nbsp;Allan Komakech ,&nbsp;Elayete Sarah ,&nbsp;Rose Nampeera ,&nbsp;Rashida Nakazzi ,&nbsp;Saharu Magona Nerima ,&nbsp;Jireh Kirabo ,&nbsp;Lilian Bulage ,&nbsp;Benon Kwesiga ,&nbsp;Alex Riolexus Ario","doi":"10.1016/j.jctube.2024.100454","DOIUrl":"https://doi.org/10.1016/j.jctube.2024.100454","url":null,"abstract":"<div><h3>Introduction</h3><p>Tuberculosis (TB) remains the leading cause of death among people living with HIV (PLHIV). TB preventive treatment (TPT) can prevent active TB infection in PLHIV for several years after it is completed. During 2019–2021, the six-month course of TPT (using isoniazid) was the most readily available in Uganda; however, program data indicated a TPT program loss to follow-up (LTFU) rate of 12 % during this period. We evaluated factors associated with TPT LTFU among PLHIV in four regional referral hospitals (RRHs) in Uganda from 2019 to 2021.</p></div><div><h3>Methods</h3><p>We abstracted program data from TPT registers on patient LTFU at Masaka, Mbale, Mubende, and Jinja RRHs. Additional data collected included client demographics, duration on HIV antiretroviral therapy (ART), year of TPT initiation, adherence, and point of entry. LTFU was defined as the failure to finish six consecutive months of isoniazid without stopping for more than two months at a time. We conducted bivariate analysis using the chi-square test for independence. Variables with <em>p</em> &lt; 0.05 in bivariate analysis were included in a logistic regression model to establish independent factors associated with LTFU.</p></div><div><h3>Results</h3><p>Overall, 24,206 clients were started on TPT in the four RRHs. Their median age was 40 years (range, 1–90 years), and 15,962 (66 %) were female. A total of 22,260 (92 %) had TPT adherence &gt;95 %. Independent factors associated with LTFU included being on ART for &lt;3 months (AOR: 3.1, 95 % CI: 2.1–4.5) and 20–24 years (AOR: 4.7, 95 % CI: 1.9–12) or 25–29 years (AOR: 3.3, 95 % CI: 1.3–8.2) compared to 15–19 years.</p></div><div><h3>Conclusions</h3><p>PLHIV just starting ART and young adults had higher odds of being LTFU from TPT during 2019–2021 in the four RRHs. Close follow-up of PLHIV aged 20–29 years and those newly initiated on ART could improve TPT completion.</p></div>","PeriodicalId":37942,"journal":{"name":"Journal of Clinical Tuberculosis and Other Mycobacterial Diseases","volume":"36 ","pages":"Article 100454"},"PeriodicalIF":2.0,"publicationDate":"2024-06-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S240557942400041X/pdfft?md5=fe04fb7d02af7172039d0436010484e3&pid=1-s2.0-S240557942400041X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141303311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
COVID-19: The association between knowledge, practice, and attitude of tuberculosis infection in the university population COVID-19:大学生对肺结核感染的认知、实践和态度之间的关联
IF 2 Q3 INFECTIOUS DISEASES Pub Date : 2024-05-31 DOI: 10.1016/j.jctube.2024.100452
Ilse Faustina Fernández-Honorio , Eladio Angulo-Altamirano , Susana Marleni Atuncar-Deza , Rosmery Sabina Pozo-Enciso

Objective

The study focused on the association between knowledge, practice and attitude towards tuberculosis in the university population during the COVID-19 pandemic.

Methods

Used Jean Watson’s theory of caring in mindfulness practice and surveyed 187 nursing surveyed 187 nursing interns from three universities. The instruments (knowledge, practice and attitude questionnaires) were validated and showed high reliability (Cronbach’s α reliability Cronbach’s α = 0.814).

Results

A strong correlation was found between knowledge and practice of tuberculosis (r = 0.996, p < 0.05), indicating a significant association. However, the association between knowledge and attitude was weaker (r = 0.160, p < 0.05). The majority had knowledge (61.2 %), a neutral practice (52.2 %) and an acceptable attitude towards TB (85.4 %).

Conclusion

These findings suggest the need to strengthen anti-TB strategies, especially in times of pandemic. The inclusion of Watson’s humanistic approach can improve the well-being of inmates and the care of patients.

方法采用让-沃森(Jean Watson)的心智实践关怀理论,对三所大学的 187 名护理实习生进行了调查。结果发现肺结核的知识和实践之间存在很强的相关性(r = 0.996,p <0.05),表明两者之间存在显著的关联。然而,知识与态度之间的相关性较弱(r = 0.160,p <0.05)。大多数人对肺结核有所了解(61.2%),持中立态度(52.2%)和可接受的态度(85.4%)。纳入沃森的人文关怀方法可以改善囚犯的福祉和对病人的护理。
{"title":"COVID-19: The association between knowledge, practice, and attitude of tuberculosis infection in the university population","authors":"Ilse Faustina Fernández-Honorio ,&nbsp;Eladio Angulo-Altamirano ,&nbsp;Susana Marleni Atuncar-Deza ,&nbsp;Rosmery Sabina Pozo-Enciso","doi":"10.1016/j.jctube.2024.100452","DOIUrl":"https://doi.org/10.1016/j.jctube.2024.100452","url":null,"abstract":"<div><h3>Objective</h3><p>The study focused on the association between knowledge, practice and attitude towards tuberculosis in the university population during the COVID-19 pandemic<strong>.</strong></p></div><div><h3>Methods</h3><p>Used Jean Watson’s theory of caring in mindfulness practice and surveyed 187 nursing surveyed 187 nursing interns from three universities. The instruments (knowledge, practice and attitude questionnaires) were validated and showed high reliability (Cronbach’s α reliability Cronbach’s α = 0.814).</p></div><div><h3>Results</h3><p>A strong correlation was found between knowledge and practice of tuberculosis (r = 0.996, p &lt; 0.05), indicating a significant association. However, the association between knowledge and attitude was weaker (r = 0.160, p &lt; 0.05). The majority had knowledge (61.2 %), a neutral practice (52.2 %) and an acceptable attitude towards TB (85.4 %).</p></div><div><h3>Conclusion</h3><p>These findings suggest the need to strengthen anti-TB strategies, especially in times of pandemic. The inclusion of Watson’s humanistic approach can improve the well-being of inmates and the care of patients.</p></div>","PeriodicalId":37942,"journal":{"name":"Journal of Clinical Tuberculosis and Other Mycobacterial Diseases","volume":"36 ","pages":"Article 100452"},"PeriodicalIF":2.0,"publicationDate":"2024-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2405579424000391/pdfft?md5=f49b4ba7018ef8759e08954480dbc4d0&pid=1-s2.0-S2405579424000391-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141239428","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Exosomal microRNAs associated with tuberculosis among people living with human immunodeficiency virus 与人类免疫缺陷病毒感染者结核病有关的外泌体微RNA
IF 2 Q3 INFECTIOUS DISEASES Pub Date : 2024-05-31 DOI: 10.1016/j.jctube.2024.100453
Yujiao Jin, Yuan Liu, Wenyan Yu, Yan Zhang, Kenv Pan, Miaochan Wang, Aifang Xu

Objective

To investigate the diagnostic value of selected exosomal miRNAs for Tuberculosis (TB) among people living with human immunodeficiency virus (PLHIV).

Methods

A total of 43 adult HIV patients, including 20 diagnosed with TB and 23 controls, were enrolled. The levels of six exosomal miRNAs (miR-20a, miR-20b, miR-26a, miR-106a, miR-191, and miR-486) were measured using qRT-PCR.

Results

The levels of these six exosomal miRNAs (miR-20a, miR-20b, miR-26a, miR-106a, miR-191, and miR-486) were significantly higher in the plasma of TB patients compared to controls among PLHIV. The Receiver Operating Characteristic (ROC) curve of these six miRNAs showed a fair performance in distinguishing TB patients from controls, with Area Under Curve (AUC) values of 0.78 (95 %CI 0.63–0.93), 0.81 (95 %CI 0.67–0.95), 0.77 (95 %CI 0.61–0.93), 0.84 (95 %CI 0.70–0.98), 0.82 (95 %CI 0.68–0.95) and 0.79 (95 %CI 0.65–0.93), respectively. These miRNAs showed higher AUC values for extrapulmonary tuberculosis compared to pulmonary tuberculosis. An analysis of subgroups was performed based on CD4 + T cell count (<200 and ≥ 200 cells·µL−1). In the high CD4 count group, all these six exosomal miRNAs appeared to have higher AUC values compared to the low CD4 count group.

Conclusions

These six exosomal miRNAs could serve as potential biomarkers for diagnosing TB among PLHIV.

方法 共招募了 43 名成年艾滋病病毒感染者,包括 20 名确诊为肺结核的患者和 23 名对照组患者。结果与对照组相比,肺结核患者血浆中六种外泌体 miRNA(miR-20a、miR-20b、miR-26a、miR-106a、miR-191 和 miR-486)的水平明显较高。这六种 miRNA 的接收者操作特征曲线(ROC)显示,它们在区分结核病患者和对照组方面表现尚可,曲线下面积(AUC)值为 0.78(95 %CI 0.63-0.93)、0.81(95 %CI 0.67-0.95)、0.77(95 %CI 0.61-0.93)、0.84(95 %CI 0.70-0.98)、0.82(95 %CI 0.68-0.95)和 0.79(95 %CI 0.65-0.93)。与肺结核相比,肺外结核的这些 miRNA 的 AUC 值更高。根据 CD4 + T 细胞计数(<200 和≥200 cells-µL-1)对亚组进行了分析。结论 这六种外泌体 miRNA 可作为诊断 PLHIV 中结核病的潜在生物标记物。
{"title":"Exosomal microRNAs associated with tuberculosis among people living with human immunodeficiency virus","authors":"Yujiao Jin,&nbsp;Yuan Liu,&nbsp;Wenyan Yu,&nbsp;Yan Zhang,&nbsp;Kenv Pan,&nbsp;Miaochan Wang,&nbsp;Aifang Xu","doi":"10.1016/j.jctube.2024.100453","DOIUrl":"https://doi.org/10.1016/j.jctube.2024.100453","url":null,"abstract":"<div><h3>Objective</h3><p>To investigate the diagnostic value of selected exosomal miRNAs for Tuberculosis (TB) among people living with human immunodeficiency virus (PLHIV).</p></div><div><h3>Methods</h3><p>A total of 43 adult HIV patients, including 20 diagnosed with TB and 23 controls, were enrolled. The levels of six exosomal miRNAs (miR-20a, miR-20b, miR-26a, miR-106a, miR-191, and miR-486) were measured using qRT-PCR.</p></div><div><h3>Results</h3><p>The levels of these six exosomal miRNAs (miR-20a, miR-20b, miR-26a, miR-106a, miR-191, and miR-486) were significantly higher in the plasma of TB patients compared to controls among PLHIV. The Receiver Operating Characteristic (ROC) curve of these six miRNAs showed a fair performance in distinguishing TB patients from controls, with Area Under Curve (AUC) values of 0.78 (95 %CI 0.63–0.93), 0.81 (95 %CI 0.67–0.95), 0.77 (95 %CI 0.61–0.93), 0.84 (95 %CI 0.70–0.98), 0.82 (95 %CI 0.68–0.95) and 0.79 (95 %CI 0.65–0.93), respectively. These miRNAs showed higher AUC values for extrapulmonary tuberculosis compared to pulmonary tuberculosis. An analysis of subgroups was performed based on CD4 + T cell count (<200 and ≥ 200 cells·µL<sup>−1</sup>). In the high CD4 count group, all these six exosomal miRNAs appeared to have higher AUC values compared to the low CD4 count group.</p></div><div><h3>Conclusions</h3><p>These six exosomal miRNAs could serve as potential biomarkers for diagnosing TB among PLHIV.</p></div>","PeriodicalId":37942,"journal":{"name":"Journal of Clinical Tuberculosis and Other Mycobacterial Diseases","volume":"36 ","pages":"Article 100453"},"PeriodicalIF":2.0,"publicationDate":"2024-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2405579424000408/pdfft?md5=80a636858ebad9760cc675c5c2671012&pid=1-s2.0-S2405579424000408-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141239429","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Clinical Tuberculosis and Other Mycobacterial Diseases
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1